Basics: short version, verdict first People Molecules Peptides Biomarkers Studies Stem Cells Editorial Methodology
← All ingredients
Cognitive

Bacopa Monnieri · Bacopa monnieri

Ayurvedic memory herb with modest but real effects at 300 mg/day.

B
Evidence grade
Human RCTs, biomarker outcomes

Short answer

One of the better-studied nootropic herbs. Look for bacosides 45%+.

Product and dose overview

Bacopa Monnieri (Bacopa monnieri) is a cognitive with evidence grade B, meaning it is supported by human RCTs. We track 2 products containing Bacopa Monnieri. Typical doses range from 300 to 450 mg per serving. The top-ranked product scores 7.8 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $29.99 per month.

Evidence grade: B Products in database: 2 Category: Cognitive

Top Bacopa Monnieri products

ProductBrandDosePrice/mo3rd-party testedScore
Bacognize Bacopa monnieri CapsulesNootropics Depot300 mg$29.99Yes7.8
Bacopa Monnieri Extract SupplementDouble Wood Supplements450 mg$17.95Yes7.7

Scores are editorial judgments, not a scientific standard. See how we score.

What it is

An Ayurvedic wetland herb used for memory. Slow-acting, takes 8 to 12 weeks.

Why people take it

Meta-analyses show small but consistent memory improvements at 300 mg/day of standardised extract.

Our verdict

One of the better-studied nootropic herbs. Look for bacosides 45%+.

Structure & class

Bacosides A and B standardised.

Mechanism & clinical data

Kongkeaw 2014 meta-analysis confirmed memory effects.

Pharmacokinetics

Chronic effect (~12 weeks).

Dose & forms

Trial dose
300 mg
/ day
Range in trials
300 to 600 mg
/ day
Common forms
BacoMind®, Standardised extract

What to watch out for

Can cause GI upset. Take with food. Not for immediate results.

Where this dose comes from

The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.

When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.

Regulatory status

EUFood supplement (varies by country)
USDietary supplement
UKFood supplement
CANHP

Timeline

Regulatory events, evidence grade changes, and key research milestones for Bacopa Monnieri, most recent first. Studies link to the paper; regulatory entries name and link the responsible authority.

  • 2025-04 Regulatory single source
    EU Court sharpens the bar for botanical health claims
    A Court of Justice of the European Union ruling in April 2025 further tightened the requirements for how botanical ingredients (herbs, plant extracts) can be marketed with health claims in the EU, effectively removing much of the flexibility of the on-hold list.
  • 2024-06 Regulatory confirmed
    EU report identifies 117 supplement substances as potential health risks
    The HoA Working Group on Food Supplements (26 European countries) published its first report evaluating 117 substances used in food supplements. Of these, 65 were assessed as likely novel foods, 6 were already regulated, 34 had insufficient data, and 12 were prioritized for Article 8 restriction under Regulation (EC) No 1925/2006. The 12 priority substances include ashwagandha, curcumin, melatonin, piperine, St. John's wort, coumarin, p-synephrine, maca, holy basil, Melaleuca, black cohosh, and L-tryptophan. The report drew on 1,500 RASFF alerts reviewed between 2017 and mid-2022.
    Source →
  • 2012 Research milestone
    Pase et al. 2012 meta-analysis (9 RCTs)
    A meta-analysis of 9 RCTs (437 subjects) found Bacopa monnieri significantly improved cognition, particularly speed of attention, versus placebo.
    Source →
  • 2010 Research milestone
    Morgan & Stevens 2010 (memory RCT)
    In 98 healthy adults over 55, 12 weeks of Bacopa monnieri (300 mg/day) significantly improved verbal learning and delayed recall versus placebo, with mild GI side effects.
    Source →
  • 2008 Research milestone
    Calabrese et al. 2008 (elderly RCT)
    In a 54-person, 12-week RCT of adults 65+, Bacopa monnieri (300 mg/day) significantly improved delayed recall memory and Stroop task performance compared to placebo.
    Source →
  • 2006-12 Regulatory confirmed
    EU Health Claims Regulation adopted
    Regulation (EC) No 1924/2006 laid down harmonised rules for nutrition and health claims made on foods, including supplements. Only claims listed in the EU Register of authorised claims can be used. Rejected botanical claims are held in a separate on-hold list.
    Source →
  • 1997 Regulatory confirmed
    EU introduces the Novel Food Regulation
    Regulation (EC) No 258/97 required any food or food ingredient without a history of consumption in the EU before 15 May 1997 to be authorised before being placed on the market. This is the framework that captures NMN, spermidine as a supplement ingredient, urolithin A, and many other longevity actives.
    Source →

Landmark studies

Found in these products (2)

All products in our catalog that contain Bacopa Monnieri, ranked by our overall score. Ranking is editorial, never paid.

Cognition
Active per serving
Bacopa Monnieri 300 mgCapsule · 120 servings
Price per serving
$0.25$29.99 · 120 servings
Testing
3rd-party listed · public lab certificate

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 7.8/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$0.25
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with nootropicsdepot.com
Double Wood Supplements
Bacopa Monnieri Extract Supplement
Cognition
Active per serving
Bacopa Monnieri 450 mgCapsule · 90 servings
Price per serving
$0.20$17.95 · 90 servings
Testing
3rd-party listed · public lab certificate

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 7.7/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$0.13
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with doublewoodsupplements.com
Editorial guides

Buying guides and comparisons

Neighbouring molecules

Related ingredients

See all in Cognitive →

Molecules in the same class, plus the actives most often formulated alongside Bacopa Monnieri in our catalogue.

Choline (CDP/Alpha-GPC)Csame categoryCiticolineBsame categoryAlpha-GPCCsame categoryPhosphatidylserineCsame category
Product shelves
See all in Cognition (2)

See Bacopa Monnieri in context: the mechanism it acts through, the biomarker it moves, the products that dose it, and the trials that tested it.

View Bacopa Monnieri on the Longevity Map →

Frequently asked questions

What is Bacopa Monnieri?

An Ayurvedic wetland herb used for memory. Slow-acting, takes 8 to 12 weeks.

What dose of Bacopa Monnieri should I take?

The trial dose in published human studies is 300 mg per day, with a range of 300 to 600 mg per day. Always consult a qualified clinician before starting any supplement.

Is Bacopa Monnieri safe?

Can cause GI upset. Take with food. Not for immediate results.

What is the best Bacopa Monnieri supplement?

We track 2 products containing Bacopa Monnieri. The top-ranked product scores 7.8 out of 10 on our composite scale, which evaluates dose, evidence, price, third-party testing, and transparency. See the comparison table above. Scores are editorial judgments, not a scientific standard.

What is the evidence grade for Bacopa Monnieri?

Bacopa Monnieri has evidence grade B, meaning it is supported by human RCTs. Grade A means replicated human RCTs with hard endpoints. Grade B means human RCTs with biomarker outcomes. Grade C means mixed or small human trials. See our evidence grading methodology.

Independently checked

Data verification

Evidence grade
B
Human RCTs, biomarker outcomes
Research dose
300 mg
Products tracked
2
Updated continuously
Safety signal
Can cause GI upset. Take with food. Not for immediate res...

Evidence grades are reviewed when new human RCTs are published. Product counts update automatically as new products are added. Dose ranges reflect published trial data, not brand recommendations. Read how we verify.